GATA3 rs2155219: Understanding Your Genetic Risk for Allergies
The rs2155219 variant is a genetic change located within the GATA3 gene, which plays a critical role in the immune system. Research suggests this variant may influence the development of allergic conditions like allergic rhinitis and asthma by modulating T-cell differentiation.
What each genotype means
Baseline allergy risk profile
This genotype represents the homozygous state for the major allele. Research indicates this variant is associated with allergic rhinitis and atopic dermatitis, though the specific functional impact of this intronic site remains an area of ongoing study.
This genotype is common in European populations, occurring in approximately 34% of individuals based on a minor allele frequency of roughly 0.42.
Intermediate allergy risk profile
Carrying one copy of each allele places you in the heterozygous group for this variant. Studies suggest this locus near GATA3 may modulate Th2 immune cell differentiation, which is relevant to allergic sensitization, though individual risk is influenced by many other genetic and environmental factors.
This is the most frequent genotype in European populations, found in approximately 48% of individuals.
Elevated allergy risk profile
This genotype represents the homozygous state for the minor allele, which has been identified in genome-wide association studies as a risk factor for allergic rhinitis and eczema. Because this variant is intronic and regulatory, it may influence how GATA3 expression is controlled during immune responses, though this does not guarantee the development of any specific condition.
This genotype is carried by approximately 18% of people of European ancestry and is less common in East Asian populations.
What is rs2155219?
The rs2155219 variant is a single nucleotide polymorphism (SNP) located in an intronic region of the GATA3 gene. Introns are non-coding sections of DNA that reside within a gene; while they do not provide the direct instructions for building a protein, they often contain regulatory elements that act like switches to control when and how much of a gene's product is made. In the case of rs2155219, its location suggests it may influence the expression of the GATA3 protein. Because this variant is situated in a regulatory area, it is studied for its potential to alter the fine-tuned balance of immune responses. Scientists identify this specific location on chromosome 10 to better understand how subtle variations in our genetic code can contribute to complex, multi-factorial health conditions like allergies.
The Role of GATA3 in Immunity
The GATA3 gene provides instructions for creating a transcription factor, a protein that binds to specific DNA sequences to regulate the activity of other genes. GATA3 is widely recognized as a master regulator of the immune system, specifically in the development and function of type 2 helper T cells (Th2 cells). Th2 cells are essential for fighting off certain parasites, but they are also the primary drivers of allergic inflammation. When GATA3 is highly active, it promotes the production of cytokines that trigger allergic responses, such as the inflammation seen in asthma and allergic rhinitis. Because GATA3 is so central to this pathway, researchers have investigated it as a potential therapeutic target. By understanding how variants like rs2155219 influence GATA3, scientists hope to gain deeper insights into why some individuals are more prone to allergic sensitization than others.
Evidence and Associations
Current research into rs2155219 classifies it as having limited evidence regarding its direct clinical impact. While genome-wide association studies (GWAS) have identified GATA3 as a significant locus for allergic traits, the specific contribution of the rs2155219 variant remains a subject of ongoing investigation. It is important to note that asthma and allergic rhinitis are complex conditions influenced by a combination of many genetic variants and environmental triggers, such as allergens, pollution, and lifestyle factors. No single SNP, including rs2155219, acts as a definitive predictor of disease. The association between this variant and allergic outcomes is statistical, meaning it is observed across large populations rather than being a direct cause of disease in an individual. Consequently, this information should be viewed as a piece of a much larger, complex biological puzzle rather than a diagnostic tool.
What You Can Do With This Information
Genetic information regarding variants like rs2155219 is primarily educational and should not be used to diagnose or treat any medical condition. If you have concerns about asthma, allergic rhinitis, or other immune-related symptoms, the most effective step is to consult with a healthcare professional, such as an allergist or immunologist. They can evaluate your clinical history, perform physical examinations, and conduct standard diagnostic tests to determine the best course of action for your health. Never make changes to your medications or treatment plans based on genetic data without first discussing them with your clinician or pharmacist. Understanding your genetic predispositions can be a helpful conversation starter with your doctor, but it does not replace professional medical advice, which is tailored to your unique health profile and current symptoms.
How common is this variant?
The minor allele frequency for rs2155219 is approximately 0.42 in European populations and 0.33 in East Asian populations, indicating that the variant is relatively common across these groups.
Frequently asked questions
Does having the GATA3 variant mean I will develop asthma?
No. Genetic variants like rs2155219 only indicate a statistical association with a trait, not a guarantee of disease. Asthma is a complex condition influenced by many genes and environmental factors.
Can I use this SNP to test for allergies?
No. Genetic testing for this SNP is not a clinical diagnostic tool for allergies. Allergies are diagnosed by doctors through clinical evaluation, skin prick tests, or blood tests for specific antibodies.
Is GATA3 a target for asthma medication?
Research has explored targeting GATA3 mRNA to reduce allergic inflammation in clinical trials. However, these are experimental approaches and not standard clinical treatments for the general public.
Should I change my allergy medication based on my genotype?
Absolutely not. You should never alter your medication regimen based on genetic information without consulting your doctor or pharmacist, as they must consider your full medical history.
Sources & further reading
Educational information only, last refreshed 9/26/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2155219?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in GATA3
Associated with various traits in GWAS, including immune-related phenotypes and blood cell counts.
This variant is associated with immune-related traits and susceptibility to certain allergic conditions.
Variant in the GATA3 locus associated with allergic sensitization and allergic disease risk.
Regulatory variant in GATA3 associated with atopic dermatitis and IgE levels in large-scale GWAS.
An intergenic variant residing in a regulatory chromatin region significantly associated with risk of allergic rhinitis.
This SNP is associated with susceptibility to breast cancer and variations in hormone receptor status.